Related Experiment Video
Updated: Jul 18, 2026
08:05
A Prediction Error-driven Retrieval Procedure for Destabilizing and Rewriting Maladaptive Reward Memories in Hazardous Drinkers
Published on: January 5, 2018
Preventing postmarketing changes in recommended doses and marketing withdrawals
1UCSF Center for Drug Development Science, Washington, DC 20036, USA. carl_peck@compuserve.com
Ernst Schering Research Foundation Workshop
|November 23, 2006
Summary
Postmarketing dosage changes in new drugs, like reductions or increases, can harm patients and manufacturers. Optimizing drug dosage with clinical pharmacology before approval can prevent these issues and market withdrawals.
Area of Science:
- Pharmacology
- Drug Safety
- Regulatory Science
Background:
- Recent prescription drug market withdrawals highlight the importance of premarketing safety research.
- Postmarketing dosage adjustments (reductions and increases) in newly marketed drugs are less recognized but linked to some withdrawals.
- These dosage changes can significantly impact patients, manufacturers, and regulatory bodies.
Purpose of the Study:
- To examine the frequency and implications of postmarketing dosage changes and market withdrawals.
- To explore strategies for preventing these adverse events through optimized pre-approval drug development.
Main Methods:
- Review of postmarketing surveillance data.
- Analysis of market withdrawal reports.
- Evaluation of clinical pharmacology's role in pre-approval dosage optimization.
Main Results:
- Postmarketing dosage changes are a notable issue with significant consequences.
- Market withdrawals are sometimes preceded by dosage adjustments.
- Targeted clinical pharmacology investigations can mitigate risks.
Conclusions:
- Intensive, targeted clinical pharmacology studies are crucial for optimizing drug dosage before Phase III trials and regulatory approval.
- Proactive dosage optimization can prevent harmful postmarketing events and market withdrawals.
- Addressing postmarketing dosage changes is essential for patient safety and drug development efficiency.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:24Dosage Regimen: Individualization
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...